Pipeline

Pipeline

Nippon Shinyaku Co., Ltd., has been developing compounds in several therapeutic fields, including hematological malignancies and intractable/orphan diseases, in Japan/China and the US/EU. In the US, NS Pharma, Inc., has been developing NS-018 (for myelofibrosis) and NS-065/NCNP-01 (for Duchenne muscular dystrophy) on behalf of Nippon Shinyaku Co., Ltd.

USA

Stage Code No. 
(generic name)
Therapeutic
field
Indications Origin Development
US : Phase I/II NS-018 hematologic
malignancies
myelofibrosis Nippon
Shinyaku
NS Pharma
US : Phase II NS-065/NCNP-01 intractable /
orphan
diseases
Duchenne
muscular
dystrophy
Nippon
Shinyaku,
NCNP
NS Pharma

NCNP : National Center of Neurology and Psychiatry